10-Q: TELA Bio Reports Q3 Revenue Growth, Secures $70M Credit

TELA Bio, Inc. announced its third-quarter 2025 results, reporting a 9% revenue increase to $20.7 million and a 17% reduction in net loss, alongside a new $70 million credit facility and a $13 million direct offering.

Summary

• Revenue for the three months ended September 30, 2025, increased by 9% to $20.7 million, up from $19.0 million in the prior year period.
• Revenue for the nine months ended September 30, 2025, increased by 15% to $59.4 million, up from $51.7 million in the prior year period.
• Net loss for the three months ended September 30, 2025, decreased by 17% to $8.6 million, compared to $10.4 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased by 4% to $29.8 million, compared to $28.6 million in the prior year period, primarily due to a $7.6 million gain on product line sale in 2024 not recurring.
• Gross margin remained stable at 68% for both the three and nine months ended September 30, 2025 and 2024.
• Cash and cash equivalents were $29.7 million as of September 30, 2025, down from $52.7 million at December 31, 2024.
• The accumulated deficit reached $388.5 million as of September 30, 2025.
• Subsequent to the quarter, TELA Bio closed a $70.0 million credit facility with Perceptive Advisors and executed an underwriting agreement for a $13.0 million registered direct offering.

Sentiment

Score: 7

Explanation: The company demonstrated solid revenue growth and a reduced net loss in the third quarter. While the nine-month net loss increased, this was primarily due to a one-time gain in the prior year. Crucially, the subsequent debt refinancing and direct offering significantly bolster liquidity and extend the company's financial runway, addressing a major concern for a company with recurring losses. Product development and market expansion continue.

Positives

• Q3 2025 revenue increased by 9% to $20.7 million, driven by new customers, growing international sales, and the U.S. launch of new larger-sized PRS configurations.
• Nine-month 2025 revenue increased by 15% to $59.4 million, reflecting strong overall growth.
• Q3 2025 net loss decreased by 17% to $8.6 million, indicating improved operational efficiency.
• Unit sales volume for OviTex increased by 22% for both the three and nine months ended September 30, 2025.
• Unit sales volume for OviTex PRS increased by 3% in Q3 2025 and 12% for the nine months ended September 30, 2025.
• Successfully secured a new $70.0 million credit facility from Perceptive Advisors post-period end, extending debt maturity to November 14, 2030, with interest-only payments until maturity.
• Executed an underwriting agreement for a $13.0 million registered direct offering, further bolstering liquidity.
• Sales and marketing expenses decreased by 8% in Q3 2025 and 4% for the nine months ended September 30, 2025, demonstrating operational leverage.
• Interest expense decreased by 11% in Q3 2025 and 10% for the nine months ended September 30, 2025, due to a decrease in the variable component of the interest rate.
• Received FDA approval for an investigational device exemption for OviTex PRS in implant-based breast reconstruction in October 2024, advancing product development.

Negatives

• The company has incurred recurring losses and negative cash flows from operations since inception, with an accumulated deficit of $388.5 million as of September 30, 2025.
• Cash and cash equivalents decreased from $52.7 million at December 31, 2024, to $29.7 million at September 30, 2025, prior to the recent financing events.
• Working capital decreased from $62.5 million at December 31, 2024, to $39.1 million at September 30, 2025.
• Net loss for the nine months ended September 30, 2025, increased by 4% to $29.8 million, compared to $28.6 million in the prior year, primarily due to the absence of a $7.6 million gain on product line sale in 2024.
• Average selling prices for hernia products decreased due to a product mix shift towards smaller-sized units.
• Other income decreased by 55% in Q3 2025 and 11% for the nine months ended September 30, 2025, primarily due to foreign currency translation adjustments.
• Research and development expenses increased by 14% in Q3 2025 and 5% for the nine months ended September 30, 2025.
• General and administrative expenses increased by 7% for both the three and nine months ended September 30, 2025.

Risks

• Uncertainty of product development and commercial acceptance of new products.
• Impact of macroeconomic conditions, including general economic slowdown or recession, inflationary pressures, banking instability, monetary policy changes, and geopolitical conflicts (Russia-Ukraine, Middle East, China-Taiwan).
• Cybersecurity events affecting or disrupting hospital operations, potential hospital closures, and constraints on the supply of critical surgical and hospital supplies.
• Ability to compete successfully with larger competitors in a highly competitive industry.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for current and future products.
• Decreasing selling prices and pricing pressures.
• Potential impact of healthcare reform in the U.S., including the Inflation Reduction Act of 2022, and global measures to reduce healthcare costs.
• Imposition of tariffs on imported products, such as the 15% U.S. tariff on medical devices from New Zealand, which could lead to increased product prices and impact demand.
• Financial strain suffered by hospital customers potentially affecting demand, reimbursement rates, and adoption of new products.
• Ability to obtain additional capital to finance planned operations on favorable terms, or at all, which could lead to delays or reductions in development, commercialization, and marketing plans.
• Dilution for stockholders if additional equity or equity-linked securities are issued.
• Debt financing may involve covenants restricting operations or ability to incur additional debt.
• Ability to develop and maintain corporate infrastructure, including internal controls.
• Ability to establish and maintain intellectual property protection and operate without infringing the intellectual property rights of others.
• Occurrence of adverse safety events, restrictions on use with products, or product liability claims.

Future Outlook

The company anticipates incurring additional losses for the foreseeable future but believes its existing cash resources, inclusive of the recently secured $70.0 million credit facility and the $13.0 million direct offering, will be sufficient to meet capital requirements and fund operations for at least the next 12 months. Management expects cost of revenue to increase in absolute dollars with sales volume growth, while sales and marketing and general and administrative expenses are projected to decrease as a percentage of revenue. Research and development expenses as a percentage of revenue are expected to vary. The company plans to continue developing new product variations, enhancing existing products, and exploring lower-cost, higher-margin devices, as well as additional complementary technologies. Further FDA interactions are anticipated to support a pre-market application for OviTex PRS in breast reconstruction.

Management Comments

• "We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients own anatomy."
• "We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide."
• "We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market."
• "Based on our current business plan, we believe that our existing cash resources inclusive of the proceeds received in the debt refinancing and proceeds to be received upon the closing of the underwritten registered direct offering, each of which is described above will be sufficient to meet our capital requirements, debt repayment obligations and fund our operations for at least the next 12 months from the issuance of this Quarterly Report."

Industry Context

TELA Bio operates in the highly competitive medical technology sector, specializing in soft-tissue reconstruction, including hernia repair and plastic surgery. The U.S. hernia repair market represents approximately 1.2 million procedures annually, with an estimated addressable market of $1.8 billion for OviTex products and $800 million for OviTex PRS products. The industry faces ongoing macroeconomic challenges such as inflation, interest rate fluctuations, supply chain disruptions, cybersecurity threats to hospitals, and financial strain on healthcare providers. Regulatory changes, including healthcare reform like the Inflation Reduction Act of 2022, and global cost-reduction measures also influence market dynamics and reimbursement policies.

Comparison to Industry Standards

• The BRAVO study for OviTex reported a 24-month recurrence rate of 2.6% in a patient population where 78% were characterized as high risk for surgical site occurrences (SSOs), suggesting strong clinical performance in a challenging patient group.
• Non-human primate data for OviTex PRS demonstrated more rapid tissue integration and tissue remodeling compared to the market-leading biologic matrix used in plastic and reconstructive surgery, indicating a potential competitive advantage.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• The company has an exclusive manufacturing and long-term supply and license agreement with Aroa Biosurgery Ltd. for OviTex and OviTex PRS products. The company purchases product from Aroa at a fixed transfer cost as a percentage of Aroa's cost of goods sold, subject to a true-up adjustment, resulting in an amount equal to 27% of net sales of OviTex and OviTex PRS products (with an exception for OviTex IHR product configurations).

Stakeholder Impact

• Shareholders face potential dilution from the recent direct offering and any future equity raises, but benefit from significantly improved liquidity and extended financial runway due to the new credit facility and offering.
• Customers (hospitals and surgeons) benefit from continued product innovation, such as larger OviTex PRS sizes and OviTex IHR for robotic procedures, and ongoing clinical data generation, aiming for optimized clinical outcomes and cost-effectiveness.
• Employees are impacted by stock-based compensation plans, with 3,683,609 shares available for future issuances under the amended 2019 Equity Incentive Plan.
• Creditors (Perceptive Advisors) now hold the primary debt facility, which offers more favorable terms (longer maturity, interest-only payments) compared to the repaid MidCap facility, indicating a more stable debt structure for the company.

Next Steps

• Evaluate and finalize the clinical study protocol for OviTex PRS in implant-based breast reconstruction and anticipate additional FDA interactions to support a pre-market application.
• Devote research and development resources to develop additional variations of OviTex and OviTex PRS products, including longer-acting resorbable polymers and packaging enhancements.
• Explore the development of lower-cost, higher-margin resorbable polymer-based devices targeting current indications.
• Explore additional technologies that may complement existing products or expand the product portfolio within the hernia, plastic and reconstruction, and broader soft-tissue reconstruction market.
• Continue to contract with additional Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) to increase access to and penetration of hospital accounts.
• Assess the impact of the One Big Beautiful, Bill Act (OBBBA) on consolidated financial statements.
• Evaluate the expected impact of new FASB Accounting Standards Updates (ASU 2023-09, ASU 2024-03, ASU 2025-06, ASU 2025-05) on consolidated financial statements and disclosures.
• Close the underwritten registered direct offering on November 17, 2025.
• Achieve net revenue thresholds by April 30, 2027, to draw an additional $10.0 million from the Perceptive credit facility.

Key Dates

Recommendation

While TELA Bio demonstrates solid revenue growth and a reduced net loss in the third quarter, it continues to operate with a significant accumulated deficit and negative cash flow from operations. The recent capital raise and debt refinancing are crucial for liquidity and extend the financial runway, mitigating immediate going concern risks. However, the company still needs to demonstrate a clear path to sustained profitability. The product pipeline and market expansion are positive, but macroeconomic risks and the competitive landscape remain challenging. A 'Hold' recommendation reflects the improved financial stability and growth potential, balanced against the ongoing losses and the need for continued execution towards profitability.

Keywords

Soft-tissue reconstruction, Hernia repair, Abdominal wall reconstruction, Plastic and reconstructive surgery, OviTex, OviTex PRS, Medical technology, Medical devices, Biologic matrices, SEC filing, 10-Q, Financial results, Perceptive Advisors, Credit facility, Direct offering